Physician profile
Benjamin Wu
NPI 1275639502
$15,902.42
in general payments reported to CMS, 2019-2025
35 companies · $3,890 in 2025
The $3,890 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,450 · 2020: $798 · 2021: $1,802 · 2022: $1,725 · 2023: $1,778 · 2024: $3,461 · 2025: $3,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,087 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,086.66 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,149.35 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $2,127.32 | 2019-2025 | Repatha, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,838.96 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Glaxosmithkline, LLC. | $1,597.10 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Gilead Sciences, INC. | $1,276.20 | 2019-2025 | Vemlidy, Livdelzi |
| Bayer Healthcare Pharmaceuticals INC. | $753.50 | 2022-2025 | |
| Novo Nordisk INC | $628.95 | 2019-2025 | Wegovy, Ozempic |
| Abbvie INC. | $609.14 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $388.23 | 2019-2025 | Zoryve |
| Boston Scientific Corporation | $385.27 | 2019-2023 | Opticross |
| Esperion Therapeutics, INC. | $362.10 | 2021-2025 | Nexletol |
| Insmed, INC. | $357.15 | 2019-2025 | Brinsupri |
| Lilly USA, LLC | $300.23 | 2019-2023 | Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $236.20 | 2019-2021 | |
| Angiodynamics, INC. | $209.56 | 2023-2024 | Nanoknife, Bioflo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $190.39 | 2023-2025 | Cologuard Collection Kit |
| Alcon Vision LLC | $147.33 | 2025 | Hydrus Microstent |
| Abbott Laboratories | $136.15 | 2022 | |
| Medtronic, INC. | $135.29 | 2022 | |
| Nestle Healthcare Nutrition INC. | $133.10 | 2020-2023 | |
| Pfizer INC. | $125.49 | 2019-2024 | |
| Ibsa Pharma INC. | $125.00 | 2021 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.80 | 2019-2024 | Xifaxan, Trulance |
| Cumberland Pharmaceuticals, INC. | $91.08 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $90.46 | 2019-2020 | |
| Ardelyx, INC. | $44.44 | 2024 | Ibsrela |
| Astellas Pharma US INC | $42.86 | 2019 | |
| Cordis US Corp. | $39.08 | 2025 | Mynx Control Venous |
| Horizon Therapeutics Plc | $33.76 | 2022 | |
| Allergan, INC. | $33.63 | 2019 | |
| Agios Pharmaceuticals, INC. | $21.87 | 2025 | Pyrukynd |
| Ironwood Pharmaceuticals, INC | $19.40 | 2021 | |
| Aimmune Therapeutics, INC. | $17.90 | 2025 | Zenpep |
| Biohaven Pharmaceuticals, INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.